SGI
BMRN icon

Summit Global Investments’s BioMarin Pharmaceuticals BMRN Stock Holding History

Summit Global Investments’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.87M Sell
32,667
-46,388
-59% -$2.54M 0.1% 103
2026
Q1 		$4.47M Sell
79,055
-144
-0.2% -$8.4K 0.26% 50
2025
Q4 		$4.71M Sell
79,199
-39,019
-33% -$2.12M 0.28% 43
2025
Q3 		$6.4M Sell
118,218
-7,676
-6% -$439K 0.37% 41
2025
Q2 		$6.92M Buy
125,894
+76,406
+154% +$4.5M 0.41% 43
2025
Q1 		$3.5M Buy
+49,488
New +$3.33M 0.25% 62

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Summit Global Investments's BMRN Position: Q2 2026 in Review

Summit Global Investments reduced its BioMarin Pharmaceuticals (BMRN) stake by 59% in Q2 2026, selling an estimated $2.54M and leaving 32,667 shares worth $1.87M. The position accounts for 0.1% of the portfolio, ranked #103.

Summit Global Investments first reported a position in BMRN in Q1 2025 and has held it in 6 quarters since. The position peaked at $6.92M in Q2 2025. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Summit Global Investments held 32,667 shares of BioMarin Pharmaceuticals worth $1.87M as of Q2 2026.
  • Summit Global Investments sold 46,388 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $2.54M.
  • BioMarin Pharmaceuticals made up 0.1% of Summit Global Investments's portfolio in Q2 2026, its #103 holding.
  • Summit Global Investments first reported a position in BioMarin Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
  • Summit Global Investments's BioMarin Pharmaceuticals position peaked at $6.92M in Q2 2025.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Summit Global Investments's 13F filing for Q2 2026, filed 3 Aug 2026.